10-Q 1 b76636e10vq.htm HAEMONETICS CORPORATION e10vq
Table of Contents

 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the quarter ended: June 27, 2009
Commission File Number: 1-10730
HAEMONETICS CORPORATION
(Exact name of registrant as specified in its charter)
     
Massachusetts   04-2882273
(State or other jurisdiction
of incorporation or organization)
  (I.R.S. Employer Identification No.)
400 Wood Road, Braintree, MA 02184
(Address of principal executive offices)
Registrant’s telephone number, including area code: (781) 848-7100
Indicate by check mark whether the registrant (1.) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) (2.) has been subject to the filing requirements for at least the past 90 days.
Yes þ     No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes o     No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act (Check one):
Large accelerated filer þ Accelerated filer o  Non-accelerated filer o
(Do not check if a smaller reporting company)
Smaller reporting company o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.)
Yes o     No þ
The number of shares of $.01 par value common stock outstanding as of June 27, 2009:
25,688,383
 
 

 


 

HAEMONETICS CORPORATION
INDEX
         
    PAGE  
PART I. FINANCIAL INFORMATION
       
 
       
       
    2  
 
       
    3  
 
       
    4  
 
       
    5  
 
       
    6  
 
       
    22  
 
       
    34  
 
       
    35  
 
       
    36  
 
       
    36  
 
       
    38  
 EX-10Y Change in Control Agreement
 EX-31.1 Section 302 Certification of the Chief Executive Officer
 EX-31.2 Section 302 Certification of the Chief Financial Officer
 EX-32.1 Section 906 Certification of the Chief Executive Officer
 EX-32.2 Section 906 Certification of the Chief Financial Officer

1


Table of Contents

ITEM 1. FINANCIAL STATEMENTS
HAEMONETICS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(Unaudited in thousands, except per share data)
                 
    Three months ended  
    June 27,     June 28,  
    2009     2008  
 
               
Net revenues
  $ 154,087     $ 144,116  
Cost of goods sold
    71,144       71,079  
 
           
Gross profit
    82,943       73,037  
 
           
 
               
Operating expenses:
               
 
               
Research, development and engineering
    6,777       5,844  
Selling, general and administrative
    49,839       47,859  
 
           
Total operating expenses
    56,616       53,703  
 
           
 
               
Operating income
    26,327       19,334  
Interest expense
    (214 )     (24 )
Interest income
    157       654  
Other (expense)/income, net
    (335 )     375  
 
           
Income before provision for income taxes
    25,935       20,339  
Provision for income taxes
    7,862       5,998  
 
           
 
               
Net income
  $ 18,073     $ 14,341  
 
           
 
               
Basic income per common share
               
Net income
  $ 0.70     $ 0.56  
 
               
Income per common share assuming dilution
               
Net income
  $ 0.69     $ 0.54  
 
               
Weighted average shares outstanding
               
Basic
    25,658       25,607  
Diluted
    26,201       26,517  
The accompanying notes are an integral part of these consolidated financial statements

2


Table of Contents

HAEMONETICS CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)
                 
    June 27, 2009     March 28, 2009  
    (Unaudited)          
ASSETS
               
Current assets:
               
Cash and cash equivalents
  $ 173,822     $ 156,721  
Accounts receivable, less allowance of $3,033 at June 27, 2009 and $2,312 at March 28, 2009
    114,161       113,598  
Inventories, net
    76,097       76,522  
Deferred tax asset, net
    8,473       7,190  
Prepaid expenses and other current assets
    23,601       28,362  
 
           
Total current assets
    396,154       382,393  
Property, plant and equipment:
               
Land, building and building improvements
    43,611       42,540  
Plant equipment and machinery
    113,373       108,572  
Office equipment and information technology
    61,744       52,461  
Haemonetics equipment
    201,924       194,290  
 
           
Total property, plant and equipment
    420,652       397,863  
Less: accumulated depreciation
    (270,265 )     (260,056 )
 
           
Net property, plant and equipment
    150,387       137,807  
Other assets:
               
Other intangibles, less amortization of $27,349 at June 27, 2009 and $25,508 at March 28, 2009
    72,008       65,261  
Goodwill
    64,730       56,426  
Deferred tax asset, long term
    3,765       3,007  
Other long-term assets
    4,898       4,799  
 
           
Total other assets
    145,402       129,493  
 
           
Total assets
  $ 691,943     $ 649,693  
 
           
 
               
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
Current liabilities:
               
Notes payable and current maturities of long-term debt
  $ 17,200     $ 695  
Accounts payable
    23,448       20,652  
Accrued payroll and related costs
    21,369       30,771  
Accrued income taxes
    1,788       2,833  
Other liabilities
    40,247       37,912  
 
           
Total current liabilities
    104,052       92,863  
 
               
Long-term debt, net of current maturities
    5,160       5,343  
Long-term deferred tax liability
    5,871       3,129  
Other long-term liabilities
    13,007       8,474  
 
               
Commitments and contingencies (Note 13)
               
Stockholders’ equity:
               
 
               
Common stock, $0.01 par value; Authorized - 150,000,000 shares; Issued and outstanding— 25,688,383 shares at June 27, 2009 and 25,622,449 shares at March 28, 2009
    257       256  
Additional paid-in capital
    232,221       226,829  
Retained earnings
    327,589       309,516  
Accumulated other comprehensive income
    3,786       3,283  
 
           
Total Stockholders’ equity
    563,853       539,884  
 
           
Total liabilities and stockholders’ equity
  $ 691,943     $ 649,693  
 
           
The accompanying notes are an integral part of these consolidated financial statements.

3


Table of Contents

HAEMONETICS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY AND OTHER COMPREHENSIVE INCOME
(Unaudited in thousands)
                                                         
                                    Accumulated        
                    Additional           Other   Total    
    Common Stock   Paid-in   Retained   Comprehensive   Stockholders’   Comprehensive
    Shares   $’s   Capital   Earnings   Income / (Loss)   Equity   Income
     
 
                                                       
Balance, March 28, 2009
    25,622     $ 256     $ 226,829     $ 309,516     $ 3,283     $ 539,884          
             
Employee stock purchase plan
    33       1       1,456                   1,457          
Exercise of stock options and related tax benefit
    33             1,157                   1,157          
Stock Compensation expense
                2,779                   2,779          
Net income
                      18,073             18,073       18,073  
Foreign currency translation adjustment
                            2,631       2,631       2,631  
Unrealized loss on hedges
                                    (1,008 )     (1,008 )     (1,008 )
Reclassification of hedge gain to earnings
                            (1,120 )     (1,120 )     (1,120 )
 
                                                       
Comprehensive income
                                        18,576  
             
 
                                                       
Balance, June 27, 2009
    25,688     $ 257     $ 232,221     $ 327,589     $ 3,786     $ 563,853          
             
The accompanying notes are an integral part of these consolidated financial statements.

4


Table of Contents

HAEMONETICS CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited in thousands)
                 
    Three Months Ended  
    June 27,     June 28,  
    2009     2008  
Cash Flows from Operating Activities:
               
Net income
  $ 18,073     $ 14,341  
Adjustments to reconcile net income to net cash provided by operating activities:
               
Non cash items:
               
Depreciation and amortization
    10,058       7,986  
Stock compensation expense
    2,779       2,367  
Loss on sales of plant, property and equipment
    99       1,352  
Unrealized (gain)/loss from hedging activities
    (1,519 )     1,985  
Accretion of interest expense on contingent consideration
    200        
 
               
Change in operating assets and liabilities:
               
Decrease/(increase) in accounts receivable, net
    1,222       (10,448 )
Decrease/(increase) in inventories
    625       (4,865 )
Decrease/(increase) in prepaid income taxes
    6,737       (639 )
Decrease/(increase) in other assets and other long-term liabilities
    (3,633 )     (5,658 )
Tax benefit of exercise of stock options
    173       604  
(Decrease)/increase in accounts payable and accrued expenses
    (9,108 )     6,817  
 
           
Net cash provided by operating activities
    25,706       13,842  
 
               
Cash Flows from Investing Activities:
               
Capital expenditures on property, plant and equipment
    (21,204 )     (12,395 )
Proceeds from sale of property, plant and equipment
    201       2,476  
Acquisition of Neoteric
    (6,613 )      
Acquisition of Medicell
    (307 )     (2,362 )
 
           
Net cash used in investing activities
    (27,923 )     (12,281 )
 
               
Cash Flows from Financing Activities:
               
Payments on long-term real estate mortgage
    (183 )     (155 )
Net increase in short-term revolving credit agreements
    16,505       3,178  
Employee stock purchase plan
    1,457       1,396  
Exercise of stock options
    909       4,779  
Excess tax benefit on exercise of stock options
    156       1,282  
Stock repurchase
          (24,945 )
 
           
Net cash provided by/(used in) financing activities
    18,844       (14,465 )
Effect of exchange rates on cash and cash equivalents
    474       (362 )
 
           
 
               
Net Increase/(Decrease) in Cash and Cash Equivalents
    17,101       (13,266 )
Cash and Cash Equivalents at Beginning of Year
    156,721       133,553  
 
           
Cash and Cash Equivalents at End of Period
  $ 173,822     $ 120,287  
 
           
 
               
Non-cash Investing and Financing Activities:
               
Transfers from inventory to fixed assets for placements of Haemonetics equipment
  $ 2,024     $ 993  
 
           
 
               
Supplemental Disclosures of Cash Flow Information:
               
Interest paid
  $ 130     $ 139  
 
           
Income taxes paid
  $ 2,980     $ 3,923  
 
           
The accompanying notes are an integral part of these consolidated financial statements

5


Table of Contents

1. BASIS OF PRESENTATION
Our accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”) in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of our management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. All significant intercompany transactions have been eliminated. Certain reclassifications were made to prior year balances to conform with the presentation of the financial statements for the three months ended June 27, 2009. Operating results for the three month period ended June 27, 2009 are not necessarily indicative of the results that may be expected for the full fiscal year ending April 3, 2010, or any other interim period. These unaudited consolidated financial statements should be read in conjunction with our audited consolidated financial statements and footnotes included in our annual report on Form 10-K for the fiscal year ended March 28, 2009.
Our fiscal year ends on the Saturday closest to the last day of March. Fiscal year 2010 includes 53 weeks with each of the first three quarters having 13 weeks and the fourth quarter having 14 weeks. Fiscal year 2009 included 52 weeks with all four quarters having 13 weeks.
Revenue Recognition
Our revenue recognition policy is to recognize revenues from product sales, software and services in accordance with SAB No. 104, “Revenue Recognition” , EITF 00-21, “Revenue Arrangements with Multiple Deliverables” and Statement of Position (“SOP”) 97-2, “Software Revenue Recognition, as amended”. These standards require that revenues are recognized when persuasive evidence of an arrangement exists, product delivery, including customer acceptance, has occurred or services have been rendered, the price is fixed or determinable and collectibility is reasonably assured. When more than one element such as equipment, disposables and services are contained in a single arrangement, we allocate revenue between the elements based on each element’s relative fair value, provided that each element meets the criteria for treatment as a separate unit of accounting. An item is considered a separate unit of accounting if it has value to the customer on a stand alone basis and there is objective and reliable evidence of the fair value of the undelivered items. The fair value of the undelivered elements is determined by the price charged when the element is sold separately, or in cases when the item is not sold separately, by using other objective evidence as defined in EITF 00-21, or vendor specific objective evidenced under SOP 97-2.
Product Revenues
Product sales consist of the sale of our equipment devices and the related disposables used with these devices. On product sales to end customers, revenue is recognized when both the title and risk of loss have transferred to the customer as determined by the shipping terms and all obligations have been completed. Examples of common post delivery obligations are installation and training. For product sales to distributors, we recognize revenue for both equipment and disposables upon shipment of these products to our distributors. Our standard contracts with our distributors state that title to the equipment passes to the distributors at point of shipment to a distributor’s location. The distributors are responsible for shipment to the end customer along with installation, training and acceptance of the equipment by the end customer. All shipments to distributors are at contract prices and payment is not contingent upon resale of the product.

6


Table of Contents

Software SolutionsRevenues
At this time, our software solutions business principally provides support to our plasma and blood collection customers. Through our Haemonetics Software Solutions unit, we provide information technology platforms and technical support for donor recruitment, blood and plasma testing laboratories, and for efficient and compliant operations of blood and plasma collection centers. For plasma customers, we also provide information technology platforms for managing distribution of plasma from collection centers to plasma fractionation facilities. Software license revenues are generally billed periodically, monthly or quarterly and recognized for the period for which the service is provided. Our software solutions business model includes the provision of services, including in some instances hosting, technical support, and maintenance, for the payment of periodic, monthly or quarterly fees. We recognize these fees and charges as earned, typically as these services are provided during the contract period.
Subsequent Events
The company has evaluated subsequent events through August 5, 2009 (the date the unaudited financial statements were issued) and has determined that there were no recognized and no non-recognized events to be disclosed.
2. RECENT ACCOUNTING PRONOUNCEMENTS
In December 2007, the FASB issued SFAS No. 141 (revised 2007), “Business Combinations” (“SFAS 141(R)”). In SFAS 141(R), the FASB retained the fundamental requirements of Statement No. 141 to account for all business combinations using the acquisition method (formerly the purchase method) and for an acquiring entity to be identified in all business combinations. However, the new standard requires the acquiring entity in a business combination to recognize all (and only) the assets acquired and liabilities assumed in the transaction; establishes the acquisition-date fair value as the measurement objective for all assets acquired and liabilities assumed; and requires the acquirer to disclose to investors and other users all of the information they need to evaluate and understand the nature and financial effect of the business combination. SFAS 141(R) is effective for annual periods beginning on or after December 15, 2008. This statement became effective for our fiscal year 2010 and its impact is reflected in our financial position and results of operations for the three months ended June 27, 2009.
In December 2007, the FASB issued FASB No. 160 “Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB No. 51” of which the objective is to improve the relevance, comparability, and transparency of the financial information that a reporting entity provides in its consolidated financial statements by establishing accounting and reporting standards by requiring all entities to report noncontrolling (minority) interests in subsidiaries in the same way—as equity in the consolidated financial statements. Moreover, Statement 160 eliminates the diversity that currently exists in accounting for transactions between an entity and noncontrolling interests by requiring they be treated as equity transactions. FASB No. 160 is effective for annual periods beginning on or after December 15, 2008. This statement became effective during fiscal year 2010 and did not have an impact on our financial position and results of operations. The company’s recent acquisition of L’Attitude Medical Systems, Inc. (“Neoteric”) was accounted for under SFAS 141(R)—see Note 9.
3. EARNINGS PER SHARE (“EPS”)
The following table provides a reconciliation of the numerators and denominators of the basic and diluted earnings per share computations, as required by SFAS Statement No. 128, “Earnings Per Share.” Basic EPS is computed by dividing net income by weighted average shares outstanding. Diluted EPS includes the effect of potentially dilutive common shares.

7


Table of Contents

                 
    For the Three Months Ended  
    June 27, 2009     June 28, 2008  
    (in thousands, except per share amounts)  
Basic EPS
               
Net income
  $ 18,073     $ 14,341  
 
               
Weighted average shares
    25,658       25,607  
 
           
Basic income per share
  $ 0.70     $ 0.56  
 
           
 
               
Diluted EPS
               
Net income
  $ 18,073     $ 14,341  
 
               
Basic weighted average shares
    25,658       25,607  
Net effect of common stock equivalents
    543       910  
 
           
Diluted weighted average shares
    26,201       26,517  
 
               
Diluted income per share
  $ 0.69     $ 0.54  
 
           
Weighted average shares outstanding, assuming dilution, excludes the impact of 1.3 million stock options for the first quarter of fiscal year 2010 and 0.4 million stock options for the first quarter of fiscal year 2009 because these securities were anti-dilutive during the noted periods.
4. STOCK-BASED COMPENSATION
Stock-based compensation expense of $2.8 and $2.4 million was recognized for the three months ended June 27, 2009 and June 28, 2008. The related income tax benefit recognized was $0.8 and $0.7 million for the three months ended June 27, 2009 and June 28, 2008. We recognize stock-based compensation on a straight line basis.
For a more detailed description of our stock-based compensation plans, see Note 11—Capital Stock to the Company’s consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 28, 2009. Our stock-based compensation plans currently consist of stock options, restricted stock awards, restricted stock units and an employee stock purchase plan. Options become exercisable in the manner specified by the Compensation Committee of our Board of Directors. All options, restricted stock awards and restricted stock units granted to employees in the three months ended June 27, 2009 vest over a four year period of time and the options expire not more than 7 years from the date of grant.
Cash flows relating to the benefits of tax deductions in excess of compensation cost recognized (in our reported or proforma results) are reported as a financing cash flow, rather than as an operating cash flow. This excess tax benefit was $0.2 million and $1.3 million for the three months ended June 27, 2009 and June 28, 2008, respectively.
A summary of information related to stock options is as follows:

8


Table of Contents

                                 
                    Weighted     Aggregate  
            Weighted     Average     Intrinsic  
    Shares Options     Average Exercise     Remaining     Value  
    Outstanding     Price     Life (Years)     ($000’s)  
Outstanding at March 28, 2009
    3,054,724     $ 42.54       4.23     $ 37,601  
 
                           
 
                               
Granted
    32,845     $ 55.37                  
Exercised
    (32,462 )   $ 28.00                  
Forfeited
    (6,716 )   $ 49.75                  
 
                           
Outstanding at June 27, 2009
    3,048,391     $ 42.82       4.03     $ 43,917  
 
                           
 
                               
Exercisable at June 27, 2009
    2,033,800     $ 38.53       3.45     $ 37,963  
 
                           
 
                               
Expected to Vest at June 27, 2009
    2,826,640     $ 42.18       3.95     $ 42,512  
 
                           
The total intrinsic value of options exercised during the three month periods ended June 27, 2009 and June 28, 2008, was $0.9 million and $5.6 million, respectively.
As of June 27, 2009 and June 28, 2008, there was $10.1 million and $12.2 million, respectively, of total unrecognized compensation cost related to non vested stock options. That cost is expected to be recognized over a weighted average period of 2.1 years. The total fair value of shares fully vested during the three months ended June 27, 2009 was $8.0 million and during the three months ended June 28, 2008 was $14.1 million.
The weighted average fair value for our options granted in the first three months of 2009 and 2008 was $15.94 and $17.32, respectively. The assumptions utilized for option grants during the periods presented are as follows:
                 
    Three Months Ended
    June 27, 2009   June 28, 2008
Stock Options Black-Scholes assumptions (weighted average):
               
Volatility
    31.85 %     28.94 %
Expected life (years)
    4.9       4.9  
Risk-free interest rate
    1.79 %     2.97 %
Dividend yield
    0.00 %     0.00 %
As of June 27, 2009 and June 28, 2008, there was $0.2 and $0.4 million, respectively, of total unrecognized compensation cost related to non vested restricted stock awards. That cost is expected to be recognized over a weighted average period of 1.3 years. The total fair value of restricted stock awards vested was $0.1 million for both the three months ended June 27, 2009 and June 28, 2008.
A summary of information related to restricted stock awards is as follows:

9


Table of Contents

                 
            Weighted Average  
            Grant Date Fair  
    Shares     Value  
Nonvested at March 28, 2009
    10,956     $ 50.97  
 
           
 
               
Granted
           
Released
    (2,500 )   $ 48.09  
 
           
 
               
Nonvested at June 27, 2009
    8,456     $ 51.82  
 
           
As of June 27, 2009 and June 28, 2008, there was $3.6 and $2.0 million, respectively, of total unrecognized compensation cost related to non vested restricted stock units. That cost is expected to be recognized over a weighted average period of 2.9 years. The total fair value of shares fully vested was $0.0 million for both the three months ended June 27, 2009 and June 28, 2008.
A summary of information related to restricted stock units is as follows:
                 
            Weighted Average  
            Market Value at  
    Shares     Grant Date  
Nonvested at March 28, 2009
    102,302     $ 53.48  
 
           
 
               
Granted
    2,501     $ 54.09  
Vested
    (289 )   $ 52.69  
Forfeited
    (598 )   $ 52.66  
 
           
 
               
Nonvested at June 27, 2009
    103,916     $ 53.50  
 
           
As of June 27, 2009, there was $0.2 million of total unrecognized compensation expense, net of estimated forfeitures, related to the Employee Stock Purchase Plan (“ESPP”) shares. That cost is expected to be recognized over the remainder of fiscal year 2009.
During the three months ended June 27, 2009 and June 28, 2008, there were 33,183 and 31,474 shares purchased under the ESPP, respectively. They were purchased at $43.89 and $44.35 per share under the ESPP.
5. ACCOUNTING FOR SHIPPING AND HANDLING COSTS
Shipping and handling costs are included in cost of goods sold with the exception of $2.9 million and $3.1 million for the three month periods ended June 27, 2009 and June 28, 2008, respectively, that are included in selling, general, and administrative expenses. Freight is classified in cost of goods sold when the customer is charged for freight and in selling, general and administration when the customer is not explicitly charged for freight.
6. PRODUCT WARRANTIES

10


Table of Contents

We provide a warranty on parts and labor for one year after the sale and installation of each device. We also warrant our disposables products through their use or expiration. We estimate our potential warranty expense based on our historical warranty experience, and we periodically assess the adequacy of our warranty accrual and make adjustments as necessary.
                 
    For the three months ended  
    June 27, 2009     June 28, 2008  
    (in thousands)  
 
               
Warranty accrual as of the beginning of the period
  $ 1,835     $ 929  
Warranty Provision
    391       535  
Warranty Spending
    (351 )     (504 )
 
           
Warranty accrual as of the end of the period
  $ 1,875     $ 960  
 
           
7. COMPREHENSIVE INCOME
Comprehensive income is the total of net income and all other non-owner changes in stockholders’ equity. For us, all other non-owner changes are primarily foreign currency translation, the change in our net minimum pension liability, and the changes in fair value of the effective portion of our outstanding cash flow hedge contracts.
8. INVENTORIES
Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first-in, first-out method.
Inventories consist of the following:
                 
    June 27, 2009     March 28, 2009  
    (in thousands)  
Raw materials
  $ 25,367     $ 23,778  
Work-in-process
    4,002       8,732  
Finished goods
    46,728       44,012  
 
           
 
  $ 76,097     $ 76,522  
 
           
9. GOODWILL, OTHER INTANGIBLE ASSETS, AND ACQUISITIONS
Goodwill
The change in the carrying amount of our goodwill during the three months ended June 27, 2009 is as follows (in thousands):

11


Table of Contents

         
Carrying amount as of March 28, 2009
  $ 56,426  
L’Attitude Medical Systems Inc. (Neoteric) (a)
    6,979  
Altivation Software Inc. (b)
    437  
Medicell Ltd. (c)
    583  
Effect of change in rates used for translation
    305  
 
     
Carrying amount as of June 27, 2009
  $ 64,730  
 
     
 
(a)   A description of the acquisition of L’Attitude Medical Systems, Inc. (“Neoteric”), which occurred on April 16, 2009, is included later in this footnote.
 
(b)   See Note 3, Acquisitions, in our fiscal year 2009 Form 10-K for a full description of the acquisition of Altivation Software (“Altivation”), which occurred on March 27, 2009.
 
(c)   See Note 3, Acqusitions, in our fiscal year 2009 Form 10-K for a full description of the acquisition of Medicell Ltd. (“Medicell”), which occurred on April 4, 2008.
Other Intangible Assets
As of June 27, 2009
                         
            Accumulated        
    Gross Carrying Amount     Amortization     Weighted Average  
    (in thousands)     (in thousands)     Useful Life (in years)  
Patents
  $ 12,039     $ 5,195       11  
Capitalized software
    20,250       661       6  
Other technology
    35,788       12,100       10  
Customer contracts and related relationships
    30,175       9,048       12  
Trade names
    1,105       345       7  
 
                   
Total intangibles
  $ 99,357     $ 27,349       10  
 
                   
As of March 28, 2009
                         
            Accumulated        
    Gross CarryingAmount     Amortization     Weighted Average  
    (in thousands)     (in thousands)     Useful Life (in years)  
Patents
  $ 12,008     $ 4,945       11  
Capitalized software
    18,994       572       6  
Other technology
    28,784       11,501       10  
Customer contracts and related relationships
    29,886       8,240       12  
Trade names
    1,097       250       7  
 
                   
Total intangibles
  $ 90,769     $ 25,508       11  
 
                   
On April 16, 2009, Haemonetics acquired the outstanding shares of L’Attitude Medical Systems Inc. (“Neoteric”). Neoteric is a medical information management company that markets a full end-to-end suite of products to track, allocate, release, and dispense hospital blood units while controlling inventory and recording

12


Table of Contents

the disposition of blood. The acquisition strategically broadened Haemonetics’ blood management solutions. The purchase price was $6.7 million plus contingent consideration.
The contingent consideration is based upon annual revenue growth for the three years following the acquisition, at established profitability thresholds. Using projected revenues for fiscal years 2010, 2011, and 2012, an analysis was performed that probability weighted three performance outcomes for the noted years. The performance outcomes were then discounted using a discount rate commensurate with the risks associated with Neoteric to arrive at a recorded $5.0 million fair value for the contingent consideration. The contingent consideration is based upon future operating performance and is not contractually limited.
The purchase price premium was recorded as goodwill of $7.0 million, other intangibles of $7.1 million, and deferred tax liabilities of $2.3 million. The purchase price allocation will be finalized no later than one year from the acquisition date. The results of the Neoteric operations are included in our consolidated results for periods after the acquisition.
In addition to the Neoteric acquisition discussed above, changes to the net carrying value of our intangible assets from March 28, 2009 to June 27, 2009, reflect the capitalization of software costs associated with our devices and software products (see Note 16), amortization expense and the effect of exchange rate changes in the translation of our intangible assets held by our international subsidiaries.
Amortization expense for amortized intangible assets was $1.6 million and $1.5 million for the three months ended June 27, 2009 and June 28, 2008, respectively. Annual amortization expense is expected to approximate $7.7 million for fiscal year 2010, $7.5 million for fiscal year 2011, $7.1 million for fiscal year 2012, $7.0 million for fiscal year 2013, and $7.6 million for fiscal year 2014.
10. DERIVATIVES AND FAIR VALUE MEASUREMENTS
We manufacture, market and sell our products globally. Approximately 51% of our sales are generated outside the U.S. in local currencies. We also incur certain manufacturing, marketing and selling costs in international markets in local currency. Accordingly, our earnings and cash flows are exposed to market risk from changes in foreign currency exchange rates relative to the U.S. dollar, our reporting currency.
We have a program in place that is designed to mitigate our exposure to changes in foreign currency exchange rates. That program includes the use of derivative financial instruments to minimize for a period of time, the unforeseen impact on our financial results from changes in foreign exchange rates. We utilize forward foreign currency contracts to hedge the anticipated cash flows from transactions denominated in foreign currencies, primarily the Japanese Yen and the Euro, and to lesser extent the Great British Pound Sterling and the Canadian Dollar. This does not eliminate the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation.
Designated Foreign Currency Hedge Contracts
All of our designated foreign currency hedge contracts as of June 27, 2009 and March 28, 2009 were cash flow hedges under Statement No. 133. We record the effective portion of any change in the fair value of designated foreign currency hedge contracts in other comprehensive income (OCI) in the Statement of Stockholders’ Equity until the related third-party transaction occurs. Once the related third-party transaction occurs, we reclassify the effective portion of any related gain or loss on the designated foreign currency hedge contracts to earnings. In the event the hedged forecasted transaction does not occur, or it becomes probable that it will not occur, we would reclassify the amount of any gain or loss on the related cash flow hedge to earnings at that time. We had

13


Table of Contents

designated foreign currency hedge contracts outstanding in the contract amount of $133.3 million as of June 27, 2009 and $117.1 million as of March 28, 2009.
During the first quarter of fiscal year 2010, we recognized net gains of $1.1 million in earnings on our cash flow hedges. All currency cash flow hedges outstanding as of June 27, 2009 mature within twelve months. For the quarter ended June 27, 2009, $1.0 million of losses, net of tax, were recorded in OCI to recognize the effective portion of the fair value of any designated foreign currency hedge contracts that are, or previously were, designated as foreign currency cash flow hedges, as compared to net gains of $2.9 million as of June 28, 2008. For the quarter ended June 27, 2009, $1.0 million of losses, net of tax, may be reclassified to earnings within the next twelve months.
Non-designated Foreign Currency Contracts
We manage our exposure to changes in foreign currency on a consolidated basis to take advantage of offsetting transactions and balances. We use currency forward contracts as a part of our strategy to manage exposure related to foreign currency denominated monetary assets and liabilities. These currency forward contracts are not designated as cash flow or fair value hedges under Statement No. 133. These forward contracts are marked-to-market with changes in fair value recorded to earnings; and are entered into for periods consistent with currency transaction exposures, generally one month. We had currency designated foreign currency hedge contracts under Statement No. 133 outstanding in the contract amount of $41.4 million as of June 27, 2009 and $51.6 million as of March 28, 2009.
Fair Value of Derivative Instruments
The following table present the effect of our derivative instruments designated as cash flow hedges and those not designated as hedging instruments under Statement No. 133 in our consolidated statement of income for the three months ended June 27, 2009.
                                         
            Amount of                      
            Gain                      
    Amount of     Reclassified                      
    Loss     OCI into from             Amount        
    Recognized in     Earnings     Location in     Excluded from     Location in  
    OCI (Effective     (Effective     Statement of     Effectiveness     Statement of  
Derivative Instruments   Portion)     Portion)     Operations     Testing (*)     Operations  
(in thousands)                                        
Designated foreign currency hedge contracts
  $ (1,008 )   $ 1,120     Net revenues   $ 260     Other income
Non-designated foreign currency hedge contracts
                        (394 )   Other expense
                           
 
  $ (1,008 )   $ 1,120             $ (134 )        
                             
 
(*)   We exclude the difference between the spot rate and hedge rate from our effectiveness testing.
We did not have fair value hedges or net investment hedges outstanding as of June 27, 2009 or March 28, 2009.
Statement No. 133 requires all derivative instruments to be recognized at their fair values as either assets or liabilities on the balance sheet. We determine the fair value of our derivative instruments using the framework prescribed by FASB Statement No. 157, Fair Value Measurements, by considering the estimated amount we

14


Table of Contents

would receive or pay to sell or transfer these instruments at the reporting date and by taking into account current interest rates, currency exchange rates, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. In certain instances, we may utilize financial models to measure fair value. Generally, we use inputs that include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; other observable inputs for the asset or liability; and inputs derived principally from, or corroborated by, observable market data by correlation or other means. As of June 27, 2009, we have classified our derivative assets and liabilities within Level 2 of the fair value hierarchy prescribed by Statement No. 157, as discussed below, because these observable inputs are available for substantially the full term of our derivative instruments.
The following tables present the fair value of our derivative instruments as they appear in our consolidated balance sheets as of June 27, 2009 by type of contract and whether it is a qualifying hedge under Statement No. 133.
                         
    Location in   Balance as of   Balance as of
(in thousands)   Balance Sheet   June 27, 2009   March 28, 2009
 
 
                       
Derivative Assets:
                       
Designated foreign currency hedge contracts
  Other current assets   $ 2,753     $ 3,936  
               
 
          $ 2,753     $ 3,936  
               
 
                       
Derivative Liabilities:
                       
Designated foreign currency hedge contracts
  Other accrued liabilities   $ 4,417     $ 2,914  
               
 
          $ 4,417     $ 2,914  
               
Other Fair Value Measurements
We adopted Financial Accounting Standards Board (FASB) Statement No. 157, Fair Value Measurements, as of March 30, 2008. Statement No. 157 defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. Statement No. 157 does not require any new fair value measurements; rather, it applies to other accounting pronouncements that require or permit fair value measurements. In accordance with Staff Position No. 157-2, for the three months ended June 27, 2009, we applied Statement No. 157 to our nonfinancial assets and nonfinancial liabilities. As we did not have an impairment of any nonfinancial assets or nonfinancial liabilities, there was no disclosure required relating to our nonfinancial assets or nonfinancial liabilities.
On a recurring basis, we measure certain financial assets and financial liabilities at fair value, including our money market funds, foreign currency derivative contracts, and contingent consideration. Statement No. 157 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. We base fair value upon quoted market prices, where available. Where quoted market prices or other observable inputs are not available, we apply valuation techniques to estimate fair value.
Statement No. 157 establishes a three-level valuation hierarchy for disclosure of fair value measurements. The categorization of assets and liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy are defined as follows:
    Level 1 — Inputs to the valuation methodology are quoted market prices for identical assets or liabilities.

15


Table of Contents

    Level 2 — Inputs to the valuation methodology are other observable inputs, including quoted market prices for similar assets or liabilities and market-corroborated inputs.
 
    Level 3 — Inputs to the valuation methodology are unobservable inputs based on management’s best estimate of inputs market participants would use in pricing the asset or liability at the measurement date, including assumptions about risk.
Our money market funds carried at fair value are generally classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices.
We recognize all derivative financial instruments in our consolidated financial statements at fair value in accordance with FASB Statement No. 133, Accounting for Derivative Instruments and Hedging Activities. We determine the fair value of these instruments using the framework prescribed by Statement No. 157 by considering the estimated amount we would receive or pay to terminate these agreements at the reporting date and by taking into account current spot rates, the creditworthiness of the counterparty for assets, and our creditworthiness for liabilities. We have classified our foreign currency hedge contracts within Level 2 of the fair value hierarchy because these observable inputs are available for substantially the full term of our derivative instruments. For the quarter ended June 27, 2009, we have classified our other liabilities — contingent consideration relating to our acquisition of Neoteric within Level 3 of the fair value hierarchy because the value is determine using significant unobservable inputs.
Fair Value Measured on a Recurring Basis
Financial assets and financial liabilities measured at fair value on a recurring basis consist of the following as of June 27, 2009:
                                 
                    Significant    
    Quoted Market Prices   Significant Other   Unobservable    
    for Identical Assets   Observable Inputs   Inputs    
(in thousands)   (Level 1)   (Level 2)   (Level 3)   Total
Assets
                               
Money market funds
  $ 150,950     $     $     $ 150,950  
Forward currency exchange contracts
          2,753             2,753  
     
 
  $ 150,950     $ 2,753     $     $ 153,703  
           
Liabilities
                               
Forward currency exchange contracts
  $     $ 4,417     $     $ 4,417  
Other liabilities — contingent consideration
                5,188       5,188  
     
 
  $     $ 4,417     $ 5,188     $ 9,605  
           
A description of the methods used to determine the fair value of the Level 3 liabilities (other liabilities — contingent consideration) is included within Note 9 — Goodwill, Other Intangible Assets, and Acquisitions. The table below provides a reconcialiation of the beginning and ending Level 3 liabilities for the quarter ended June 27, 2009.

16


Table of Contents

         
    Fair Value Measurements  
    Using Significant  
    Unobservable Inputs  
(in thousands)   (Level 3)  
 
       
Beginning balance
  $  
Transfers into Level 3
    4,988  
Change in value
    200  
 
     
Ending balance
  $ 5,188  
 
     
Statement No. 159
In February 2007, the FASB issued Statement No. 159, The Fair Value Option for Financial Assets and Financial Liabilities, including an amendment of FASB Statement No. 115, which allows an entity to elect to record financial assets and financial liabilities at fair value upon their initial recognition on a contract-by-contract basis. We adopted Statement No. 159 as of March 30, 2008 and did not elect the fair value option for our eligible financial assets and financial liabilities.
Other Fair Value Disclosures
The fair value of our long-term debt obligations was $5.2 million and $5.9 million at June 27, 2009 and June 28, 2008, respectively.
11. INCOME TAXES
Our reported tax rate includes two principal components: an expected effective annual tax rate and discrete items resulting in additional provisions or benefits that are recorded in the quarter that an event arises. Events or items that give rise to discrete recognition include finalizing audit examinations for open tax years, a statute of limitation’s expiration, or a stock acquisition.
The reported tax rate was 30.3% for the three month period ended June 27, 2009. The reported tax rate includes:
  A 31.1% expected effective annual tax rate which reflects tax benefits from foreign taxes (including our Swiss principal) and a domestic manufacturing deduction, offset in part by the state tax provision, and stock compensation expenses not deductible in all jurisdictions; and
  A $0.7 million benefit (on an annual basis) from the remittance of Japanese earnings.
The reported tax rate was 29.5% for the three month period ended June 28, 2008. The reported tax rate includes:
  A 35.1% expected effective annual tax rate which reflects tax benefits from foreign taxes and stock compensation expenses that are not deductible in all jurisdictions and a domestic manufacturing deduction, offset in part by the state tax provision, and stock compensation expenses not deductible in all jurisdictions; and

17


Table of Contents

  A $1.1 million reversal of previously accrued income taxes because of the expiration of foreign statute of limitations.
We conduct business globally and, as a result, file we consolidated federal, consolidated and separate state and foreign income tax returns in multiple jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world in jurisdictions including the U.S., Japan, Germany, France, the United Kingdom, and Switzerland. With few exceptions, we are no longer subject to U.S. federal, state and local, or foreign income tax examinations for years before 2006.
12. COMMITMENTS AND CONTINGENCIES
We are presently engaged in various legal actions, and although ultimate liability cannot be determined at the present time, we believe, based on consultation with counsel, that any such liability will not materially affect our consolidated financial position or our results of operations.
13. DEFINED BENEFIT PENSION PLANS
Certain of the Company’s foreign subsidiaries have defined benefit pension plans covering substantially all full time employees at those subsidiaries. Net periodic benefit costs for the plans in the aggregate include the following components:
                 
    For the three months ended  
    June 27, 2009     June 28, 2008  
    (in thousands)  
Service Cost
  $ 124     $ 150  
Interest cost on benefit obligation
    61       66  
Expected return on plan assets
    (15 )     (19 )
Amortization of unrecognized prior service cost, unrecognized gain and unrecognized initial obligation
    (10 )     (4 )
 
           
Net periodic benefit cost
  $ 160     $ 193  
 
           
14. SEGMENT INFORMATION
Segment Definition Criteria
We manage our business on the basis of one operating segment: the design, manufacture and marketing of automated blood processing systems. Our chief operating decision-maker uses consolidated results to make operating and strategic decisions. Manufacturing processes, as well as the regulatory environment in which we operate, are largely the same for all product lines.
Enterprise Wide Disclosures about Product and Services
We have three families of products: (1) disposables, (2) software solutions and (3) equipment & other.
Disposables include the plasma, blood bank, and hospital product lines. Plasma consists of the disposables used to perform apheresis for the separation of whole blood components and subsequent collection of plasma. Blood bank consists of platelet and red cell disposables. Hospital consists of surgical disposables (principally the Cell Saver® and cardioPAT® disposable products), OrthoPAT® disposables, and diagnostics products (principally the TEG® products).

18


Table of Contents

Software solutions include information technology platforms that assist blood banks, plasma centers, and hospitals more effectively manage regulatory compliance and operational efficiency.
Equipment & other revenues include revenue from equipment sales, repairs performed under preventive maintenance contracts or emergency service visits, spare part sales, and various service and training programs.
Revenues from External Customers:
                 
    Three Months Ended  
    June 27, 2009     June 28, 2008  
    (in thousands)  
 
               
Disposable revenues by product family
               
Plasma disposables
  $ 58,869     $ 46,868  
 
               
Blood bank disposables
               
Platelet
  $ 34,307     $ 35,659  
Red cell
  $ 11,779     $ 11,842  
 
           
 
  $ 46,086     $ 47,501  
 
           
 
               
Hospital disposables
               
Surgical
  $ 17,425     $ 17,269  
OrthoPAT
  $ 8,584     $ 8,796  
Diagnostics
  $ 4,997     $ 5,094  
 
           
 
  $ 31,006     $ 31,159  
 
           
 
               
Disposables revenue
  $ 135,961     $ 125,528  
 
               
Software solutions
  $ 8,454     $ 7,258  
Equipment & other
  $ 9,672     $ 11,330  
 
           
Total revenues
  $ 154,087     $ 144,116  
 
           
15. REORGANIZATION
During the last two years, the Company has transformed aspects of its international businesses, and more recently, its U.S. domestic Technical Operations organizations. The following summarizes the restructuring activity for the three months ended June 27, 2009 and June 28, 2008, respectively:

19


Table of Contents

                                         
    Three Months Ended June 27, 2009  
                                    Restructuring  
    Balance at                             Accrual Balance at  
(Dollars in thousands)   March 28, 2009     Cost Incurred     Payments     Asset Write down     June 27, 2009  
 
                                       
Employee-related costs
  $ 2,730     $     $ (483 )   $     $ 2,247  
Facility related costs
    42                       $ 42  
Other Exit & Termination Costs
    78                       $ 78  
 
                             
 
  $ 2,850     $     $ (483 )   $     $ 2,367  
 
                             
                                         
    Three Months Ended June 28, 2008  
                                    Restructuring  
    Balance at                     Asset Write     Accrual Balance at  
(Dollars in thousands)   March 31, 2008     Cost Incurred     Payments     down     June 28, 2008  
 
                                       
Employee-related costs
  $ 521     $ 1,668     $ (1,299 )   $     $ 890  
Facility related costs
    42                       $ 42  
Other Exit & Termination Costs
    78       72       (72 )           $ 78  
 
                             
 
  $ 641     $ 1,740     $ (1,371 )   $     $ 1,010  
 
                             
16. CAPITALIZATION OF SOFTWARE DEVELOPMENT COSTS
The Company is implementing an Enterprise Resource Planning (ERP) system. In fiscal year 2007, we began our plan to implement the system in three phases over three years.
The cost of software that is developed or obtained for internal use is accounted for pursuant to AICPA Statement of Position 98-1, “Accounting for the Costs of Computer Software Developed or Obtained for Internal Use” (“SOP 98-1”). Pursuant to SOP 98-1, the Company capitalizes costs incurred during the application development stage of software developed for internal use, and expenses costs incurred during the preliminary project and the post-implementation operation stages of development. The Company capitalized $4.2 million and $0.4 million, respectively, during the three month periods ended June 27, 2009 and June 28, 2008, in costs incurred for acquisition of the software license and related software development costs for new internal software that was in the application development stage. The total capitalized costs incurred to date include $1.8 million for the cost of the software license and $25.5 million in third party development costs and internal personnel costs.
In connection with the development of the software for our next generation Donor apheresis platform, the Company capitalized $0.0 million and $0.7 million in software development costs during the three month periods ended June 27, 2009 and June 28, 2008, respectively, in accordance with SFAS No. 86, “Accounting for the Cost of Computer Software to be Sold, Leased, or Otherwise Marketed”. Since the start of the project, a total of $12.0 million in total software development costs has been capitalized in connection with the next generation Donor apheresis platform. All costs capitalized were incurred after a detailed design of the software was developed and research and development activities on the underlying device were completed. Work on the Donor apheresis platform has been temporarily suspended while the Company focuses on completing another project, which is expected to be completed during fiscal year 2010. Work on the Donor apheresis platform is expected to resume during fiscal year 2010. We will begin to amortize these costs when the device is released for sale.

20


Table of Contents

Additionally, the Company capitalized $1.3 million and $0.7 million in other software development costs for ongoing initiatives during the three-month periods ended June 27, 2009 and June 28, 2008, respectively. At June 27, 2009, we have a total of $7.2 million of costs capitalized related to other in process software development initiatives. We will begin to amortize these costs when the products are released for sale.

21


Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) should be read in conjunction with both our interim consolidated financial statements and notes thereto which appear elsewhere in this Quarterly Report on Form 10-Q and our annual consolidated financial statements, notes thereto, and the MD&A contained in our fiscal year 2009 Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”) on May 22, 2009. The following discussion may contain forward-looking statements and should be read in conjunction with the “Cautionary Statement Regarding Forward-Looking Information” beginning on page 40.
Our Business
Haemonetics is a blood management solutions company for our customers. Anchored by our reputable medical device systems, we also provide information technology platforms and value added services to provide customers with business solutions which support improved clinical outcomes for patients and efficiency in the blood supply chain.
Our systems automate the collection and processing of donated blood; assess likelihood for blood loss; and salvage and process surgical patient blood. These systems include devices and single-use, proprietary disposable sets (“disposables”) that operate only with our specialized devices. Our systems allow users to collect and process only the blood component(s) they target — plasma, platelets, or red blood cells — increasing donor and patient safety as well as collection efficiencies. Our information technology platforms are used by blood and plasma collectors to improve the safety and efficiency of blood collection logistics by eliminating previously manual functions at not-for-profit blood banks and commercial plasma centers. Our business services products include consulting, Six Sigma, LEAN manufacturing and Insight Opportunity Model offerings that support our customers’ needs for regulatory compliance and operational efficiency in the blood supply chain.
We either sell our devices to customers (resulting in equipment revenue) or place our devices with customers subject to certain conditions. When the device remains our property, the customer has the right to use it for a period of time as long as the customer meets certain conditions we have established, which among other things, generally include one or more of the following:
    Purchase and consumption of a minimum level of disposables products;
 
    Payment of monthly rental fees; and
 
    An asset utilization performance metric, such as performing a minimum level of procedures per month per device.
Our disposables revenue stream (including sales of disposables and fees for the use of our equipment) accounted for approximately 88% and 87% of our total revenues for the first quarter of fiscal year 2010 and 2009, respectively.

22


Table of Contents

Financial Summary
                         
(in thousands, except   For the three months ended   Percentage
per share data)   June 27, 2009   June 28, 2008   Increase/(Decrease)
     
     
Net revenues
  $ 154,087     $ 144,116       6.9 %
Gross profit
  $ 82,943     $ 73,037       13.6 %
% of net revenues
    53.8 %     50.7 %        
 
                       
Operating expenses
  $ 56,616     $ 53,703       5.4 %
Operating income
  $ 26,327     $ 19,334       36.2 %
% of net revenues
    17.1 %     13.4 %        
 
                       
Interest expense
    ($214 )     ($24 )     791.7 %
Interest income
  $ 157     $ 654       (76.0 %)
Other income, net
    ($335 )   $ 375       (189.3 %)
 
                       
Income before taxes
  $ 25,935     $ 20,339       27.5 %
 
                       
Provision for income tax
  $ 7,862     $ 5,998       31.1 %
% of pre-tax income
    30.3 %     29.5 %        
 
                       
Net income
  $ 18,073     $ 14,341       26.0 %
% of net revenues
    11.7 %     10.0 %        
 
                       
Earnings per share-diluted
  $ 0.69     $ 0.54       27.5 %
Net revenues increased 6.9% for the first quarter of fiscal year 2010 over the comparable period of fiscal year 2009. The effects of foreign exchange accounted for an increase of 0.7% for the first quarter. The remaining increase of 6.2% for the quarter is mainly due to increases in our plasma disposables revenue and software solutions revenue.
Gross profit increased 13.6% as compared to the first quarter of fiscal year 2009. The favorable effects of foreign exchange accounted for an increase of 8.2% for the quarter. The remaining increase of 5.4% for the quarter was due primarily to increased sales and manufacturing efficiencies. This was partly offset by changes in product mix driven by higher sales of our lower margin plasma products.
Operating expenses increased 5.4% for the first quarter of fiscal year 2010 over the comparable period of fiscal year 2009. The favorable effects of foreign exchange accounted for a decrease in operating expenses of 2.9% for the quarter. Without the effects of foreign exchange operating expenses increased 8.3% for the quarter. The higher operating expenses are primarily related to increased investment in research and development, the expenses from recent acquisitions, expenses associated with our ERP Phase II go-live, and higher expenses due to increased

23


Table of Contents

sales. The noted increases in operating expenses were partly offset by a lack of restructuring costs in the first quarter of fiscal year 2010.
Operating income increased 36.2% for the first quarter of fiscal year 2010 over the comparable period of fiscal year 2009. The favorable effects of foreign exchange accounted for an increase of operating income of 37.7% for the quarter. Without the effects of foreign exchange operating income decreased 1.5% for the quarter as a result of noted changes in gross profit and operating expenses.
Net income increased 26.0% for the first quarter of fiscal year 2010 over the comparable period of fiscal year 2009. The main factor that affected net income was the increase in operating income, partially offset by increased interest expense and other expense.
RESULTS OF OPERATIONS
Net Revenues by Geography
                         
    For the three months ended   Percentage
(in thousands)   June 27, 2009   June 28, 2008   Increase
 
                       
United States
  $ 75,013     $ 65,789       14.0 %
International
    79,074       78,327       1.0 %
     
Net revenues
  $ 154,087     $ 144,116       6.9 %
     
International Operations and the Impact of Foreign Exchange
Our principal operations are in the U.S., Europe, Japan and other parts of Asia. Our products are marketed in more than 80 countries around the world via a direct sales force as well as independent distributors and agents.
Our revenues generated outside the U.S. approximated 51% and 54% of total sales for the first quarter of fiscal years 2010 and 2009, respectively. Revenues in Japan accounted for approximately 16% and 15% of total revenues for the first quarter of fiscal year 2010 and 2009, respectively. Revenues in Europe accounted for approximately 28% and 31% of total revenues for the first quarter of fiscal year 2010 and 2009, respectively. International sales are primarily conducted in local currencies, primarily the Japanese Yen and the Euro. As discussed above, our results of operations can be impacted by changes in the value of the Yen and the Euro relative to the U.S. dollar.
Please see section entitled “Foreign Exchange” in this discussion for a more complete explanation of how foreign currency affects our business and our strategy for managing this exposure.

24


Table of Contents

Net Revenues by Product Type
                         
    For the three months ended   Percentage
(in thousands)   June 27, 2009   June 28, 2008   Increase/(Decrease)
     
 
                       
Disposables
  $ 135,961     $ 125,528       8.3 %
Software solutions
    8,454       7,258       16.5 %
Equipment & other
    9,672       11,330       (14.6 %)
     
Net revenues
  $ 154,087     $ 144,116       6.9 %
     
Disposables Revenues by Product Type
                         
    For the three months ended     Percentage  
(in thousands)   June 27, 2009     June 28, 2008     Increase/(Decrease)  
     
 
                       
Plasma disposables
  $ 58,869     $ 46,868       25.6 %
Blood bank disposables
                       
Platelet
  $ 34,307     $ 35,659       (3.8 %)
Red cell
  $ 11,779     $ 11,842       (0.5 %)
 
                   
 
  $ 46,086     $ 47,501       (3.0 %)
 
                   
Hospital disposables
                       
Surgical
  $ 17,425     $ 17,269       0.9 %
OrthoPAT
  $ 8,584     $ 8,796       (2.4 %)
Diagnostics
  $ 4,997     $ 5,094       (1.9 %)
 
  $ 31,006     $ 31,159       (0.5 %)
 
                   
 
                       
Total disposables revenue
  $ 135,961     $ 125,528       8.3 %
 
                   
DISPOSABLES
Disposables include the Plasma, Blood Bank, and Hospital product lines. Disposables revenue increased 8.3% for the first quarter of fiscal year 2010 compared to the first quarter of fiscal year 2009. Foreign exchange resulted in a 0.7% increase for the first quarter over the comparable period in fiscal year 2009. The remaining increase of 7.6% for the quarter was driven by increases in the Plasma product line, as discussed below.
Plasma
Plasma disposables revenue increased 25.6% for the first quarter of fiscal year 2010 compared to the same period in fiscal year 2009. Foreign exchange resulted in a 0.3% increase for the first quarter over the comparable period in fiscal year 2009. The remaining 25.3% increase was driven by higher collections in both the US and Europe, share gains, and, to a lesser extent, pricing.

25


Table of Contents

As supply-demand balance has been achieved between source plasma collected and used in pharmaceutical production, we are beginning to see a moderation in collections. The fractionation companies will balance collections to support the underlying growth in demand for plasma drugs which we believe to be in the 7% range. With contractual price increases, new products, and market share gains, we anticipate that plasma disposable revenue growth will continue to outpace collection market growth in the near term and moderate to a low to mid double-digit rate over the next eighteen months.
Blood Bank
Blood bank consists of platelet and red cell disposables.
Platelet disposables revenue decreased 3.8% for the first quarter of fiscal year 2010 compared to the same period in fiscal year 2009. Comparing the first quarter of fiscal year 2010 to that of 2009, foreign exchange accounted for an increase of 1.9%. Without the effect of currency, the decrease of 5.7% was the result of challenges in South Korea associated with the significant devaluation of South Korea’s currency, the Won, and share loss in Japan.
Red Cell disposables revenue decreased 0.5% compared to the first quarter of fiscal year 2009. Foreign exchange accounted for an decrease of 0.3% in the quarter over the comparable period in fiscal year 2009. The remaining decrease of 0.2% was driven by lower demand for automated collections, as a result of (i) fewer elective surgeries, thus a reduced demand for blood and (ii) 5% more donors due to the entry of 16 year olds to the blood donor population.
Hospital
Hospital consists of surgical, OrthoPAT, and diagnostics products.
Revenues from our surgical disposables increased 0.9% for the first quarter of fiscal year 2010 as compared to the first quarter of fiscal year 2009. Surgical disposables revenue consists principally of the Cell Saver and cardioPAT products. Foreign exchange resulted in a 2.3% increase in surgical disposables revenue during the quarter. Without the effect of currency, surgical disposables decreased 1.4% for the quarter. The decrease was primarily the result of decreased sales of Cell Saver products partially offset by increases in sales of cardioPAT products.
Revenues from our OrthoPAT disposables decreased 2.4% for the first quarter of fiscal year 2010 as compared to the first quarter of fiscal year 2009. Foreign exchange resulted in a 0.4% decrease in OrthoPAT disposables revenue during the quarter. Without foreign exchange, revenues decreased by 2.0% for the quarter. The decrease was primarily the result of a decline in the number of orthopedic procedures.
Revenues from our diagnostics products decreased 1.9% for the first quarter of fiscal year 2010 as compared to the first quarter of fiscal year 2009. Diagnostics product revenue consists principally of the TEG products. Foreign exchange resulted in a 2.9% decrease in diagnostic product revenue during the quarter. Without the effect of currency, diagnostic product increased 1.0% for the quarter. The growth was the result of increased TEG disposables revenue mostly offset by a decline in TEG equipment sales.
SOFTWARE SOLUTIONS
Our software solutions revenues include revenue from software sales. Software solutions revenues increased 16.5% as compared to the first quarter of fiscal year 2009. Foreign exchange resulted in a 0.9% increase in software solutions revenue during the quarter. The remaining increase of 15.6% was driven by increased sales to commercial plasma customers and revenues associated with two recent acquisitions.

26


Table of Contents

EQUIPMENT & OTHER
Our equipment & other revenues include revenue from equipment sales, repairs performed under preventive maintenance contracts or emergency service visits, spare part sales, and various service and training programs. Equipment & other revenues decreased 14.6% for the first quarter of fiscal year 2010 as compared to the first quarter of fiscal year 2009. Foreign exchange resulted in a 1.4% increase in revenue during the quarter. The remaining decrease of 16.0% is primarily the result of fewer equipment sales, particularly to our hospital customers as hospitals are resisting even modest capital purchases in the current economic environment.
Gross Profit
                         
    For the three months ended   Percentage
(in thousands)   June 27, 2009   June 28, 2008   Increase
     
 
                       
Gross profit
  $ 82,943     $ 73,037       13.6 %
 
                       
% of net revenues
    53.8 %     50.7 %        
Gross profit increased 13.6% as compared to the first quarter of fiscal year 2009. Foreign exchange resulted in a 8.2% increase for the first quarter of fiscal year 2010. The remaining increase of 5.4% for the quarter was due primarily to the increase in net revenues and fixed cost leverage. Our gross profit margin improved 310 basis points compared to the first quarter of fiscal year 2009. The improvement was attributable to foreign exchange and improved manufacturing efficiencies, particularly for our plasma business. Product mix partly offset these improvements due to increased sales of our lower margin plasma products.
Operating Expenses
                         
    For the three months ended   Percentage
(in thousands)   June 27, 2009   June 28, 2008   Increase
     
 
                       
Research, development and engineering
  $ 6,777     $ 5,844       16.0 %
 
                       
% of net revenues
    4.4 %     4.1 %        
 
                       
Selling, general and administrative
  $ 49,839     $ 47,859       4.1 %
 
                       
% of net revenues
    32.3 %     33.2 %        
 
                       
Total operating expenses
  $ 56,616     $ 53,703          
% of net revenues
    36.7 %     37.3 %        

27


Table of Contents

Research, Development and Engineering
Research, development and engineering expenses increased 16.0% for the first quarter of fiscal year 2010 as compared to the first quarter of fiscal year 2009. The increase in the quarter is a result of increased spending in the whole blood and Arryx blood diagnostics technologies.
Selling, General and Administrative
During the first quarter of fiscal year 2010, selling, general and administrative expenses increased 4.1%. Foreign exchange resulted in a 3.0% decrease in selling, general and administrative during the quarter. Excluding the impact of foreign exchange, selling, general and administrative expense increased 7.1% for the first quarter. The increase was due primarily to (i) expenses brought on from recent acquisitions (Altivation and Neoteric) that had not been reflected in the first quarter of fiscal year 2009, (ii) expenses associated with our ERP Phase II go-live, and (iii) general selling, marketing and handling costs necessary to support the 6.9% increase in sales. The noted increases were partly offset by a lack of restructuring costs in the first quarter of fiscal year 2010.
Operating Income
                         
    For the three months ended   Percentage
(in thousands)   June 27, 2009   June 28, 2008   Increase
     
 
                       
Operating income
  $ 26,327     $ 19,334       36.2 %
 
                       
% of net revenues
    17.1 %     13.4 %        
Operating income increased 36.2% for the first quarter of fiscal year 2010 as compared to the first quarter of fiscal year 2009. Foreign exchange resulted in a 37.7% increase in operating income during the quarter. Without the effects of foreign currency, operating income decreased 1.5% for the quarter due to the net of sales and gross profit growth offset by increases in operating expenses.
Other income, net
                         
    For the three months ended   Percentage
(in thousands)   June 27, 2009   June 28, 2008   Decrease
     
 
                       
Interest expense
  $ (214 )   $ (24 )        
 
                       
Interest income
    157       654          
 
                       
Other (expense)/income, net
    (335 )     375          
             
Total other income, net
  $ (392 )   $ 1,005       (139.0 %)
             
Total other income, net decreased 139.0% during the first quarter of fiscal year 2010 as compared to the first quarter of fiscal year 2009 due to the net of the (i) increase in interest expense due to the FAS 141(R) accounting relating to the contingent consideration on a recent acquisition, (ii) decrease in interest income due to significantly reduced investment yield, and (iii) decrease in other income associated with hedge points on forward contracts. Points on forward contracts are amounts, either expensed or earned, based on the interest rate differential between two foreign currencies in a forward hedge contract.

28


Table of Contents

Income Taxes
                         
    For the three months ended   Percentage
    June 27, 2009   June 28, 2008   Increase
     
 
                       
Reported income tax rate
    30.3 %     29.5 %     0.8 %
Our reported tax rate includes two principal components: an expected effective annual tax rate and discrete items resulting in additional provisions or benefits that are recorded in the quarter that an event arises. Events or items that give rise to discrete recognition include finalizing audit examinations for open tax years, a statute of limitation’s expiration, or a stock acquisition.
The reported tax rate was 30.3% for the three month period ended June 27, 2009. The reported tax rate includes:
  A 31.1% expected effective annual tax rate which reflects tax benefits from foreign taxes (including our Swiss principal) and a domestic manufacturing deduction, offset in part by the state tax provision, and stock compensation expenses not deductible in all jurisdictions; and
 
  A $0.7 million benefit (on an annual basis) from the remittance of Japanese earnings.
The reported tax rate was 29.5% for the three month period ended June 28, 2008. The reported tax rate includes:
  A 35.1% expected effective annual tax rate which reflects tax benefits from foreign taxes and stock compensation expenses that are not deductible in all jurisdictions and a domestic manufacturing deduction, offset in part by the state tax provision, and stock compensation expenses not deductible in all jurisdictions; and
 
  A $1.1 million reversal of previously accrued income taxes because of the expiration of foreign statute of limitations.
We conduct business globally and, as a result, file we consolidated federal, consolidated and separate state and foreign income tax returns in multiple jurisdictions. In the normal course of business, we are subject to examination by taxing authorities throughout the world in jurisdictions including the U.S., Japan, Germany, France, the United Kingdom, and Switzerland. With few exceptions, we are no longer subject to U.S. federal, state and local, or foreign income tax examinations for years before 2006.
Liquidity and Capital Resources
The following table contains certain key performance indicators we believe depict our liquidity and cash flow position:

29


Table of Contents

                 
    June 27, 2009   March 28, 2009
    (dollars in thousands)
Cash & cash equivalents
  $ 173,822     $ 156,721  
Working capital
  $ 292,102     $ 289,530  
Current ratio
    3.8       4.1  
Net cash position (1)
  $ 151,462     $ 150,683  
Days sales outstanding (DSO)
    67       67  
Disposables finished goods inventory turnover
    6.6       7.1  
 
(1)   Net cash position is the sum of cash and cash equivalents less total debt.
Our primary sources of capital include cash and cash equivalents, internally generated cash flows, bank borrowings and option exercises. We believe these sources to be sufficient to fund our requirements, which are primarily capital expenditures and acquisitions, new business and product development, and working capital for at least the next twelve months.
                         
    For the three months ended:     $ Increase /  
    June 27, 2009     June 28, 2008     (Decrease)  
    (dollars in thousands)          
Net cash provided by (used in):
                       
Operating activities
  $ 25,706     $ 13,842     $ 11,864  
Investing activities
    (27,923 )     (12,281 )     (15,642 )
Financing activities
    18,844       (14,465 )     33,309  
Effect of exchange rate changes on cash and cash equivalents (1)
    474       (362 )     836  
 
                 
Net increase/(decrease) in cash and cash equivalents
  $ 17,101     $ (13,266 )   $ 30,367  
 
                 
 
(1)   The balance sheet is affected by spot exchange rates used to translate local currency amounts into U.S. dollars. In accordance with GAAP, we have removed the effect of foreign currency throughout our cash flow statement, except for its effect on our cash and cash equivalents.
In May 2009, Board of Directors approved a $40 million share repurchase. At June 27, 2009, as no shares had been repurchased, we had the full $40 million remaining on the $40 million share repurchase limit set by the Board of Directors.
Cash Flow Overview:
Three Month Comparison
Operating Activities:
Net cash provided by operating activities increased by $11.9 million in the first three months of fiscal year 2010 as compared to the first three months of 2009 due primarily to:

30


Table of Contents

    $3.7 million increase in net income;
 
    $11.7 million reduced investment in accounts receivable due to improved collections over the same quarter last year;
 
    $5.5 million reduced investment in inventories; and
 
    $7.4 million reduced investment in prepaid income taxes
    partially offset by
    a $15.7 million increase in payments of accounts payable and accrued expenses, which included a $13.7 million payment of (i) the fiscal year 2009 employee performance bonuses worldwide and (ii) the discretionary bonus for extraordinary performance to all employees other than the Chief Executive Officer and certain other executives during the first quarter of fiscal year 2010.
Investing Activities:
Net cash used in investing activities increased during the first three months of fiscal year 2010 as compared to the first three months of 2009 due primarily to the $8.8 million increased spending in capital expenditures on property, plant, and equipment and the $6.6 million acquisition of Neoteric.
Financing Activities:
Net cash used in financing activities decreased by $33.3 million in the first three months of fiscal year 2010 as compared to the first three months of 2009 due primarily to:
    $24.9 million decrease in stock repurchases and
 
    $13.3 million increase in net borrowings under short-term revolving credit agreements
    partially offset by
    $3.9 million decrease in exercise of stock options and tax benefit of stock compensation.
Inflation
We do not believe that inflation had a significant impact on our results of operations for the periods presented. Historically, we believe we have been able to mitigate the effects of inflation by improving our manufacturing and purchasing efficiencies, by increasing employee productivity, and by adjusting the selling prices of products. We continue to monitor inflation pressures generally and raw materials indices that may affect our procurement and production costs. Increases in the price of petroleum derivatives could result in corresponding increases in our costs to procure plastic raw materials.
Foreign Exchange
Approximately 51% of our sales are generated outside the U.S. in local currencies, yet our reporting currency is the U.S. dollar. Foreign exchange risk arises because we engage in business in foreign countries in local currency. Exposure is partially mitigated by producing and sourcing product in local currency and expenses incurred by local sales offices. However, whenever the U.S. dollar strengthens relative to the other major currencies, there is

31


Table of Contents

an adverse affect on our results of operations and alternatively, whenever the U.S. dollar weakens relative to the other major currencies there is a positive effect on our results of operations.
Our primary foreign currency exposures in relation to the U.S. dollar are the Euro and the Japanese Yen. In response to the global economic turmoil and sharply increased volatility in the foreign exchange rates, we added to our hedge and enter into forward contracts to hedge the anticipated cash flows from forecasted Great British Pound and Canadian Dollar denominated expenses.
It is our policy to minimize for a period of time, the unforeseen impact on our financial results of fluctuations in foreign exchange rates by using derivative financial instruments known as forward contracts to hedge the anticipated cash flows from forecasted foreign currency denominated sales. Hedging through the use of forward contracts does not eliminate the volatility of foreign exchange rates, but because we generally enter into forward contracts one year out, rates are fixed for a one-year period, thereby facilitating financial planning and resource allocation. We enter into forward contracts that mature one month prior to the anticipated timing of the forecasted foreign currency denominated sales. These contracts are designated as cash flow hedges and are intended to lock in the expected cash flows of forecasted foreign currency denominated sales at the available spot rate. Actual spot rate gains and losses on these contracts are recorded in sales, at the same time the underlying transactions being hedged are recorded. The final impact of currency fluctuations on the results of operations is dependent on the local currency amounts hedged and the actual local currency results.
Presented below are the spot rates for our Euro and Japanese Yen cash flow hedges that either settled in fiscal year 2009 and the first quarter of fiscal year 2010, or are presently outstanding. These hedges cover our long foreign currency positions that result from our sales in Europe and Japan. The table also shows the relative strengthening or weakening of the spot rates associated with those hedge contracts versus the spot rates in the contracts that settled in the prior comparable period.
                                                                 
            Strengthen/   Second   Strengthen/   Third   Strengthen/   Fourth   Strengthen/
    First Quarter   (Weaken)   Quarter   (Weaken)   Quarter   (Weaken)   Quarter   (Weaken)
Euro — Hedge Spot Rate (US$  per Euro)                                                
FY09
    1.3453               1.3704               1.4396               1.4908          
FY10
    1.5681       16.6 %     1.4890       8.6 %     1.3192       (8.4 %)     1.2812       (14.1 %)
FY11
    1.3582       (13.4 %)                                                
 
                                                               
Japanese Yen — Hedge Spot Rate (JPY per US$)                                                
FY09
    120.6432               116.7411               112.8810               106.2511          
FY10
    105.2792       12.7 %     105.1132       10.0 %     96.3791       14.6 %     93.4950       12.0 %
FY11
    98.1677       6.8 %                                                
 
*   We generally place our cash flow hedge contracts on a rolling twelve month basis. Accordingly, the only hedge contracts placed for fiscal year 2011 are for the first quarter.
Recent Accounting Pronouncements
In December 2007, the FASB issued SFAS No. 141 (revised 2007), “Business Combinations” (“SFAS 141(R)”). In SFAS 141(R), the FASB retained the fundamental requirements of Statement No. 141 to account for all business combinations using the acquisition method (formerly the purchase method) and for an acquiring entity to be identified in all business combinations. However, the new standard requires the acquiring entity in a business combination to recognize all (and only) the assets acquired and liabilities assumed in the transaction; establishes the acquisition-date fair value as the measurement objective for all assets acquired and liabilities assumed; and requires the acquirer to disclose to investors and other users all of the information they need to evaluate and understand the nature and financial effect of the business combination. SFAS 141(R) is effective for annual

32


Table of Contents

periods beginning on or after December 15, 2008. This statement became effective for our fiscal year 2010 and its impact is reflected in our financial position and results of operations for the three months ended June 27, 2009.
In December 2007, the FASB issued FASB No. 160 “Noncontrolling Interests in Consolidated Financial Statements—an amendment of ARB No. 51” of which the objective is to improve the relevance, comparability, and transparency of the financial information that a reporting entity provides in its consolidated financial statements by establishing accounting and reporting standards by requiring all entities to report noncontrolling (minority) interests in subsidiaries in the same way—as equity in the consolidated financial statements. Moreover, Statement 160 eliminates the diversity that currently exists in accounting for transactions between an entity and noncontrolling interests by requiring they be treated as equity transactions. FASB No. 160 is effective for annual periods beginning on or after December 15, 2008. This statement became effective during fiscal year 2010 and did not have an impact on our financial position and results of operations. The company’s recent acquisition of L’Attitude Medical Systems, Inc. (“Neoteric”) was accounted for under SFAS 141(R)—see Note 9 to the interim consolidated financial statements.
Cautionary Statement Regarding Forward-Looking Information
Statements contained in this report, as well as oral statements we make which are prefaced with the words “may,” “will,” “expect,” “anticipate,” “continue,” “estimate,” “project,” “intend,” “designed,” and similar expressions, are intended to identify forward looking statements regarding events, conditions, and financial trends that may affect our future plans of operations, business strategy, results of operations, and financial position. These statements are based on our current expectations and estimates as to prospective events and circumstances about which we can give no firm assurance. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made. As it is not possible to predict every new factor that may emerge, forward-looking statements should not be relied upon as a prediction of our actual future financial condition or results. These forward-looking statements, like any forward-looking statements, involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. Such risks and uncertainties include technological advances in the medical field, and our standards for transfusion medicine and our ability to successfully implement products that incorporate such advances and standards, product demand and market acceptance of our products, regulatory requirements, the effect of economic and political conditions, the impact of competitive products and pricing, price volatility in petroleum products (plastics are the principal component of our disposables, which are the main source of our revenues), the impact of industry consolidation, foreign currency exchange rates, changes in customers’ ordering patterns, the effect of industry consolidation as seen in the Plasma market, the effect of communicable diseases and the effect of uncertainties in markets outside the U.S. (including Europe and Asia) in which we operate. The foregoing list should not be construed as exhaustive.

33


Table of Contents

ITEM 3. Quantitative and qualitative disclosures about market risk
The Company’s exposures relative to market risk are due to foreign exchange risk and interest rate risk.
Foreign exchange risk
See the section entitled Foreign Exchange for a discussion of how foreign currency affects our business. It is our policy to minimize for a period of time, the unforeseen impact on our financial results of fluctuations in foreign exchange rates by using derivative financial instruments known as forward contracts to hedge anticipated cash flows from forecasted foreign currency denominated sales. We do not use the financial instruments for speculative or trading activities. At June 27, 2009, we had the following significant foreign exchange contracts to hedge the anticipated cash flows from forecasted foreign currency denominated sales outstanding:
                                         
    (BUY) / SELL     Weighted Spot   Weighted Forward   Fair Value        
Hedged Currency   Local Currency     Contract Rate   Contract Rate   Gain / (Loss)     Maturity  
Euro
    7,700,000       1.449       1.424     $ 228,514     Jul 2009 - Aug 2009
Euro
    11,307,000       1.319       1.313       ($893,920 )   Sep 2009 - Nov 2009
Euro
    10,584,808       1.281       1.282       ($1,134,635 )   Dec 2009 - Feb 2010
Euro
    9,582,063       1.358       1.357       ($336,623 )   Mar 2009 - May 2010
Japanese Yen
    1,045,432,888       105.17     per US$     103.62     per US$     ($855,110 )   Jul 2009 - Aug 2009
Japanese Yen
    1,628,684,654       96.38     per US$     95.33     per US$   $ 4,070     Sep 2009 - Nov 2009
Japanese Yen
    1,394,096,500       93.50     per US$     92.58     per US$   $ 400,513     Dec 2009 - Feb 2010
Japanese Yen
    1,369,475,624       98.17     per US$     97.50     per US$     ($346,345 )   Mar 2009 - May 2010
GBP
    (856,706 )     1.433       1.433     $ 179,324     Jul 2009 - Aug 2009
GBP
    (2,639,558 )     1.423       1.423     $ 570,022     Sep 2009 - Nov 2009
GBP
    (2,274,093 )     1.405       1.406     $ 519,687     Dec 2009 - Feb 2010
GBP
    (2,276,051 )     1.471       1.472     $ 367,178     Mar 2009 - May 2010
GBP
    (954,611 )     1.628       1.627     $ 13,193     Mar 2009 - May 2010
CAD
    (3,730,057 )     1.120       1.119       ($93,389 )   Jul 2009 - Aug 2009
CAD
    (3,247,851 )     1.113       1.111       ($99,476 )   Sep 2009 - Nov 2009
CAD
    (3,761,190 )     1.088       1.086       ($186,551 )   Dec 2009 - Feb 2010
 
                                     
 
                            ($1,663,548 )        
 
                                     
We estimate the change in the fair value of all forward contracts assuming both a 10% strengthening and weakening of the U.S. dollar relative to all other major currencies. In the event of a 10% strengthening of the U.S. dollar, the change in fair value of all forward contracts would result in a $11.1 million increase in the fair value of the forward contracts; whereas a 10% weakening of the US dollar would result in a $12.7 million decrease in the fair value of the forward contracts.
Interest Rate Risk
All of our long-term debt is at fixed rates. Accordingly, a change in interest rates has an insignificant effect on our interest expense amounts. The fair value of our long-term debt, however, does change in response to interest rate movements due to its fixed rate nature. These changes reflect the premium (when market interest rates decline below the contract fixed interest rates) or discount (when market interest rates rise above the fixed interest rate) that an investor in these long term obligations would pay in the market interest rate environment.
At June 27, 2009, the fair value of our long-term debt was approximately $0.8 million higher than the value of the debt reflected on our financial statements. This higher fair market is entirely related to the $5.2 million remaining principal balance of the original $10.0 million, 8.41% real estate mortgage due January, 2016.

34


Table of Contents

Using scenario analysis, if the interest rate on all long-term maturities changed by 10% from the rate levels that existed at June 27, 2009, the fair value of our long-term debt would change by approximately $0.1 million.
ITEM 4. Controls and Procedures
We conducted an evaluation, as of June 27, 2009, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer (the Company’s principal executive officer and principal financial officer, respectively) regarding the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15 of the Securities Exchange Act of 1934 (the “Exchange Act”). Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective.
In fiscal 2007, the Company initiated a company-wide implementation of Oracle, a global enterprise resource planning (ERP) system. The Company successfully completed the final major go-live milestone implementations in the ERP system during the three months ended June 27, 2009. The ERP implementation replaced our existing production planning, manufacturing, and purchasing systems, resulting in significant changes to our business processes and therefore our controls. These changes are intended to standardize and automate business processes and controls. We believe the controls, as implemented, are appropriate and functioning effectively.
Other than the change mentioned above, no other change in the Company’s internal control over financial reporting occurred during the three months ended June 27, 2009 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

35


Table of Contents

PART II — OTHER INFORMATION
Item 1. Legal Proceedings
In December 2005, we filed a lawsuit against Baxter Healthcare SA and Fenwal Inc. in Massachusetts federal district court, seeking an injunction and damages on account of Baxter’s infringement of a Haemonetics patent, through the sale of Baxter’s ALYX brand automated red cell collection system, a competitor of our automated red cell collection systems. In March 2007, Baxter sold the Transfusion Technologies Division (which markets the ALYX product) to private investors, Texas Pacific Group and Maverick Capital, Ltd. The new company which resulted from the sale was renamed Fenwal. In January 2009, a jury found that the Fenwal ALYX system infringed Haemonetics’ patent and awarded us $15.7 million in damages for past infringement. On June 2, 2009, the court ruled that, in addition to paying the damages awarded by the jury, Fenwal must stop selling the ALYX consumable by December 1, 2010 and must pay Haemonetics a 10% royalty on ALYX consumable net sales from January 30, 2009 until December 1, 2010 when the injunction takes effect. In addition, the court awarded pre-judgment interest at 5% on the unpaid damages awarded. These rulings may be appealed by Fenwal or Baxter.
Item 1A. Risk Factors
In addition to the other information set forth in this report, careful consideration should be given to the factors discussed in Part 1, “Item 1A. Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended March 28, 2009, which could materially affect the Company’s business, financial condition or future results. The risks described in the Company’s Annual Report on Form 10-K are not the only risks facing the Company. Additional risks and uncertainties not currently known to the Company or that it currently deems to be immaterial also may materially adversely affect its business, financial condition and/or operating results.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
     Not applicable
Item 3. Defaults upon Senior Securities
     Not applicable.
Item 4. Submission of Matters to a Vote of Security Holders
     None
Item 5. Other Information
     None
Item 6. Exhibits
     
10Y
  Change in Control Agreement entered into between the Company and Brian Concannon on April 2, 2009
 
   
31.1
  Certification pursuant to Section 302 of Sarbanes-Oxley Act of 2002, of Brian Concannon, President and Chief Executive Officer of the Company

36


Table of Contents

     
31.2
  Certification pursuant to Section 302 of Sarbanes-Oxley of 2002, of Christopher Lindop, Chief Financial Officer and Vice President Business Development of the Company
 
   
32.1
  Certification Pursuant to 18 United States Code Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of Brian Concannon, President and Chief Executive Officer of the Company
 
   
32.2
  Certification Pursuant to 18 United States Code Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, of Christopher Lindop, Chief Financial Officer and Vice President Business Development of the Company

37


Table of Contents

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
         
  HAEMONETICS CORPORATION
 
 
Date: August 5, 2009  By:   /s/ Brian Concannon    
    Brian Concannon, President and Chief Executive Officer  
    (Principal Executive Officer)   
 
     
Date: August 5, 2009  By:   /s/ Christopher Lindop    
    Christopher Lindop, Chief Financial Officer and Vice President Business Development
(Principal Financial Officer) 
 
 

38